Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

InnoTACA

Financiado

Cerrado

Innovation Associate for highly specific Tumour Associated Carbohydrate Antigens

CellmAbs is a recent but fast growing biopharmaceutical spinoff dedicated to the development of immuno-oncology agents that target only cancer cells, promoting the activation of the immune system and inhibiting growth of cancer in... ver más

30/04/2022

CELLMABS SA

100K€

Presupuesto del proyecto: 100K€

Líder del proyecto

CELLMABS SA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-04-30

INNOSUP-02-2019-2020: European SME innovation Associate -... Specific Challenge:The lack of access to skills, to latest knowledge and capacity to manage innovati...

I+D

Cerrada

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

CELLMABS SA

100.08K€ | Lider

Proyectos interesantes

SweetAim

Medical Technol...

Data Science

1M€ Cerrado

MGLycan

Medical Technol...

Data Science

173K€ Cerrado

PID2020-118529RB-I00

Medical Technol...

Data Science

218K€ Cerrado

ImmunoChip

Medical Technol...

Data Science

2M€ Financiado

SweetCAR

Medical Technol...

Data Science

150K€ Cerrado

ARGONAUT

Medical Technol...

Data Science

207K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 19 meses Fecha Inicio: 2020-09-15
Fecha Fin: 2022-04-30

Líder del proyecto

CELLMABS SA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 100K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto CellmAbs is a recent but fast growing biopharmaceutical spinoff dedicated to the development of immuno-oncology agents that target only cancer cells, promoting the activation of the immune system and inhibiting growth of cancer in both early and late stages. In spite of many advances in diagnostic and treatment development, many cancers still have no targeted therapy or have limited or toxic treatment options. Early detection is crucial to optimize treatment and substantially reduce incidence and mortality. In spite of the advent of new and improved genomic and proteomic technologies, it has not been possible to identify cancer-specific therapeutic targets or molecules that are able to reliably and accurately predict outcomes during cancer management and treatment. Cancers such as colorectal cancer (CRC) have very poor standard of care and thus own an unmet need for reliable and specific targets. The discovery of tumour associate carbohydrate antigens (TACA) is very promising but is still very insipient due to lack of experts, knowledge and technology on the field. InnoTACA will address several unmet needs by presenting the grounds for hiring an Innovation Associate with relevant expertise and experience on groundbreaking technology to innovate TACA discovery to apply in cancer theranostic, combining high-quality transferable-skill training with excellent scientific training in glycomics. InnoTACA addresses the CellmAbs need of identifying highly specific TACAs, which would serve as a lead for the development of safer and more cost-effective immunotherapies, even for advanced unresectable CRC. The InnoTACA Associate and such immunotherapies will provide CellmAbs with improved products to capitalize and compete with current healthcare business and it will allow CellmAbs to connect with other high-tech SMEs focused in pharmaceutical and medical development, and partners with strong translational clinical and research backgrounds.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores